We have the second episode in a series of conversations with Dr. Thomas Dayspring today. 

The esteemed Dr. Dayspring is an expert on internal medicine and clinical lipidology. In this episode, we continue with our last conversation, diving into Lp(a) and the influences of gender, race, and menopause. We explain how estrogen is a PCSK9 inhibitor and explore the significance of brain health and risks for dementia. We tackle cholesterol synthesis and discuss the side effects of statins, clarifying who is most susceptible to their impact on the brain. We also examine the significance of the desmosterol biomarker, highlighting the level to aim for, especially when making decisions regarding cholesterol medications, and we answer one question from a listener. 

You may want to listen to this insightful conversation with the renowned Dr. Dayspring more than once. He has graciously agreed to return and film additional episodes, where we will dive into more questions from listeners. 

IN THIS EPISODE, YOU WILL LEARN:

Why Lp(a) is like a wolf in sheep's clothing for many individuals

How Lp(a) levels are higher in African Americans and women, especially after menopause 

Dr. Dayspring highlights that Lp(a) particles are even more pro-inflammatory than LDL particles

How PCSK9 inhibitors are the only drugs that significantly reduce Lp(a)

Why do women have a higher risk of dementia than men?

Dr. Dayspring explains ApoE as the key lipoprotein for brain cholesterol transport.

How statins cross the blood-brain barrier to lower brain cholesterol

Why desmosterol levels matter

New therapies that can lower ApoB and Lp(a)

Why imaging is essential for menopausal women with elevated ApoB and Lp(a)

Connect with Cynthia Thurlow  

Connect with Dr. Thomas Dayspring

On X (@Drlipid)

On LinkedIn

Journal Article: Atherosclerosis: Non-genetic influences on lipoprotein(a) concentrations 

Journal of the American Heart Association: Trajectories of Blood Lipid Profiles in Midlife Women: Does Menopause Matter?